| 摘要 |
The present invention is concerned with compounds of general formula I I wherein Z signifies a substituted phenyl, substituted pyridyl, substituted pyrimidyl or substituted indolyl group of formulae a-e & lt;IMG> a, b, c, d, and e R1 signifies hydrogen, amino, lower alkylamino, lower dialkylamino, lower alkyl, halogen or trifluoromethyl; R2 signifies hydrogen or lower alkyl; R3 signifies hydrogen, amino, lower alkylamino, lower dialkylamino, lower alkyl, CF3, lower alkoxy or halogen; R4 signifies amino, lower alkylamino, lower dialkylamino, lower alkyl, lower alkoxy or halogen; R5 signifies hydrogen, lower alkylamino, di-lower alkylamino, lower alkoxy or halogen; R6 signifies lower alkyl, lower alkylamino, di-lower alkylamino, lower alkoxy, halogen or CF3; R7 signifies amino, lower alkylamino, di-lower alkylamino, lower alkoxy, lower alkylsulphanyl, mercapto, pyrrolidin-1-yl or azetidin-1-yl; R8 signifies amino, lower alkylamino, di-lower alkylamino, benzylamino, lower alkoxy, lower alkylsulphanyl, halogen, pyrrolidin-1-yl or azetidin-1-yl; R9 and R10 each independently signify lower alkoxy or lower alkylamino; R11 signifies hydrogen or halogen; R12 signifies hydrogen or lower alkyl, and a signifies an optional double bond, with the proviso that R7 and R8 do not simultaneously signify methoxy, as well as their pharmaceutically acceptable salts as therapeutically active substances against central nervous disorders and for the production of corresponding medicaments.
|
